@article{24b117c5b1cd455b8bbf27c6e13b2563,
title = "ADVANCING INCLUSIVE RESEARCH: ESTABLISHING COLLABORATIVE STRATEGIES TO IMPROVE DIVERSITY IN CLINICAL TRIALS",
abstract = "Well-characterized disparities in clinical research have disproportionately affected patients of color, particularly in underserved communities. To tackle these barriers, Genentech formed the External Council for Advancing Inclusive Research, a 14-person committee dedicated to developing strategies to increase clinical research participation. To help improve the recruitment and retention of patients of color, this article chronicles our efforts to tangibly address the clinical research barriers at the system, study, and patient levels over the last four years. These efforts are one of the initial steps to fully realize the promise of personalized health care and provide increased patient benefit at less cost to society. Instead of simply acknowledging the problem, here we illuminate the collaborative and multilevel strategies that have been effective in delivering meaningful progress for patients.",
keywords = "COVID-19, Clinical trial design, Health care disparities, Minority health, Personalized health care",
author = "Owen Garrick and Ruben Mesa and Andrea Ferris and Kim, {Edward S.} and Edith Mitchell and Brawley, {Otis W.} and John Carpten and Carter, {Keith D.} and Joseph Coney and Robert Winn and Stephanie Monroe and Fabian Sandoval and Edith Perez and Mitzi Williams and Evan Grove and Quita Highsmith and Nicole Richie and Begelman, {Susan M.} and Collins, {Asha S.} and Jamie Freedman and Gonzales, {Melissa S.} and Gerren Wilson",
note = "Funding Information: Ruben Mesa - Receives consultant fees from Genentech/Novartis/Sierra Onc/LaJolla/ Pharma/Constellation; receives research support from Celgene/Incyte/Abbvie/Samus/ Genotech/Promedior/CTI/ Constellation Funding Information: Susan Begelman - Employee of Genentech, a member of Roche Group, and owner of Roche stock. Member, The Genentech Foundation Board, a U.S.-based, private charitable foundation whose donations are made possible by contributions from Genentech Otis Brawley - Receives consulting fees from: Genentech, EGRX, Grail; Meeting support from Lyell Immunopharma, PDS Biopharma, Jackson Labs; and owns stock or stock options in Lyell Immunopharma, PDS Biopharma, Grail. Publisher Copyright: {\textcopyright} 2022 Ethnicity and Disease, Inc.. All rights reserved.",
year = "2022",
doi = "10.18865/ed.32.1.61",
language = "English (US)",
volume = "32",
pages = "61--68",
journal = "Ethnicity and Disease",
issn = "1049-510X",
publisher = "ISHIB",
number = "1",
}